B5050
Monoclonal Anti-Brain-derived Neurotrophic Factor antibody produced in mouse
clone 35928.11, purified immunoglobulin, lyophilized powder
Synonym(s):
Anti-BDNF
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
35928.11, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 8-25 μg/mL using human spinal cord
western blot: 1-2 μg/mL
isotype
IgG1
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... BDNF(627)
Looking for similar products? Visit Product Comparison Guide
General description
The antibody shows ~5% cross-reactivity with recombinant human β−NGF and recombinant rat β−NGF.
Immunogen
Recombinant human BDNF, expressed in Sf 21 cells.
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Immunofluorescence (1 paper)
Immunofluorescence (1 paper)
Biochem/physiol Actions
Brain derived neurotrophic factor (BDNF) belongs to a family of secreted proteins called neurotrophins that includes, nerve growth factor (NGF), neurotrophin-3 (NT3) and NT4/5. BDNF is expressed in the developing and the mature brain. The downstream pathways promoted by BDNF include PI3K, MAPK and JAK/STAT. The most important role of BDNF is the regulation of synaptic transmission and plasticity, protein synthesis and phosphorylation of local proteins.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.
Preparation Note
Purified from ascites fluid using protein A.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Related product
recommended
Product No.
Description
Pricing
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kunlin Jin et al.
Proceedings of the National Academy of Sciences of the United States of America, 102(50), 18189-18194 (2005-12-06)
There is no satisfactory treatment for Huntington's disease (HD), a hereditary neurodegenerative disorder that produces chorea, dementia, and death. One potential treatment strategy involves the replacement of dead neurons by stimulating the proliferation of endogenous neuronal precursors (neurogenesis) and their
Gabriele Baj et al.
Journal of cell science, 129(14), 2852-2864 (2016-06-09)
Brain-derived neurotrophic factor (BDNF) is encoded by multiple mRNA variants whose differential subcellular distribution constitutes a 'spatial code' for local translation of BDNF and selective morphological remodeling of dendrites. Here, we investigated where BDNF translation takes place and what are
Risa Takahara-Yamauchi et al.
Biomedical research (Tokyo, Japan), 42(2), 67-76 (2021-04-13)
In this study, we employed a rodent model for persistent allodynia and hyperalgesia to determine whether voluntary exercise could exert analgesic effects on these pain symptoms. Rats were subcutaneously injected with formalin into the plantar surface of the right hind
Joanne L Jones et al.
Brain : a journal of neurology, 133(Pt 8), 2232-2247 (2010-07-28)
Treatment of early relapsing-remitting multiple sclerosis with the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) significantly reduced the risk of relapse and accumulation of disability compared with interferon β-1a in a phase 2 trial [Coles et al., (Alemtuzumab
Tsuyoshi Inagaki et al.
Neuroscience research, 61(2), 192-200 (2008-04-09)
High-frequency stimulation (HFS) induces long-term potentiation (LTP) at inhibitory synapses of layer 5 pyramidal neurons in developing rat visual cortex. This LTP requires postsynaptic Ca2+ rise for induction, while the maintenance mechanism is present at the presynaptic site, suggesting presynaptic
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service